Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Key Inclusion Criteria

1. Lp(a) ≥ 70 mg/dL at the screening visit, measured at the Central laboratory
2. Myocardial infarction: ≥ 3 months from screening and randomization to ≤ 10 years prior to the screening visit
3. Ischemic stroke: ≥ 3 months from screening and randomization to ≤ 10 years prior to the screening visit
4. Clinically significant symptomatic peripheral artery disease

Key Exclusion Criteria

1. Uncontrolled hypertension
2. Heart failure New York Heart Association (NYHA) class IV
3. History of malignancy of any organ system
4. History of hemorrhagic stroke or other major bleeding
5. Platelet count ≤LLN
6. Active liver disease or hepatic dysfunction
7. Significant kidney disease
8. Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply at the end.